Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nkarta, Inc. - Common Stock (NQ:NKTX)

2.910 +0.100 (+3.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nkarta, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month ↗
 
Via Benzinga
News headline image
Why Nkarta Stock Is Soaring Today ↗
One analyst is now more bullish about this clinical-stage biotech stock. 
Via The Motley Fool
News headline image
UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
NKTX Stock Earnings: Nkarta Beats EPS for Q2 2024 ↗
NKTX stock results show that Nkarta beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Why Serve Robotics Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
From Nkarta, Inc.
Via GlobeNewswire
News headline image
NKTX Stock Earnings: Nkarta Beats EPS for Q1 2024 ↗
NKTX stock results show that Nkarta beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
3 Undervalued Stocks Primed for a 2X Return ↗
Discover compelling investment opportunities with top undervalued stocks for high returns leading in healthcare and software. 
Via InvestorPlace
News headline image
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Opportunity Alert: 3 Undiscovered Stocks About to Explode on Wall Street’s Radar ↗
Explore these undiscovered stock picks attached with rapid growth in biotechnology, oil and gas, and pharmaceuticals. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing ↗
Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&D... 
Via Benzinga
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Nasdaq Turns Higher; Akanda Shares Plunge ↗
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Monday. The Dow traded down 0.37% to 39,331.42 while the NASDAQ rose 0.06% to 16,439.38. The S&P 500 also... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Moves Higher; US New Home Sales Fall In February ↗
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Monday. The Dow traded down 0.22% to 39,389.17 while the NASDAQ fell 0.15% to 16,410.10. The... 
Via Benzinga
Topics Stocks
News headline image
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
We are starting off the day with a breakdown of the biggest pre-market stock movers that traders need to know about on Monday morning. 
Via InvestorPlace
News headline image
Nkarta Announces Pricing of $240 Million Underwritten Offering
From Nkarta, Inc.
Via GlobeNewswire
News headline image
Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results. 
Via Benzinga
News headline image
Stocks Level Off, S&P 500 Nears Best Week Of 2024, NVIDIA Rallies For 11th Week, Bitcoin Sinks: What's Driving Markets Friday? ↗
Stocks slightly retreated during New York’s morning session on Friday, following another robust week of gains fueled by a dovish Federal Reserve meeting, which underscored Chair Jerome Powell‘s... 
Via Benzinga
Topics Economy Stocks
News headline image
Why Is Cancer Drug-Developer Nkarta Stock Trading Lower On Friday? ↗
Nkarta closed patient enrollment in NKX101 clinical trial, reallocating focus to lead program NKX019 for autoimmune disease. Recent expansion into autoimmune disease with FDA clearance for NKX019 in... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.